Locations:
Search IconSearch

Cancer

Tumor-Infiltrating Lymphocytes (TIL) therapy
January 6, 2025/Cancer/News & Insight

Tumor-Infiltrating Lymphocytes Therapy Now Available for Treating Unresectable or Metastatic Melanoma

Cleveland Clinic Cancer Institute among select group of centers to administer highly personalized treatment

Woman with breast cancer
January 2, 2025/Cancer/News & Insight

Real-World Insights of KEYNOTE-522 Regimen Adoption for Treating Triple-Negative Breast Cancer

Real-world results reporting aims to make treatments safer and more effective

DNA strand
December 31, 2024/Cancer/News & Insight

New Data Further Support Breast Cancer Polygenic Risk Score

Ongoing clinical validation in diverse populations refine breast cancer risk substratification

Dr. Dermawan
December 24, 2024/Cancer/News & Insight

New Genomic Models for Leiomyosarcoma Treatment (Podcast)

Soft tissue pathologist discusses research into incorporating genomic data to improve risk stratification

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Illustration of gut microbes
December 23, 2024/Urology & Nephrology

Bladder Cancer: Optimizing Treatment Response Through the Gut Microbiome

Research program sets the stage for clinical trials

smartwatch being strapped to a woman's wrist
December 20, 2024/Neurosciences/Brain Tumor

Can Smartwatch Data Predict Progression and Detect Complications in Patients With Glioblastoma?

Researchers use AI tools to compare clinical events with continuous patient monitoring

Dr. Shahzad Raza
December 18, 2024/Cancer/News & Insight

Researchers Explore Prognostic Value of Transcriptomic Data in Multiple Myeloma

Prediction and bioinformatic data could prove valuable for therapeutic interventions targeting this malignancy

3D rendering of bispecific antibodies
December 17, 2024/Cancer/Blood Cancers

Efficacy and Safety Outcomes of Bispecific Antibodies

Study measures real-world outcomes for relapsed or refractory large B-cell lymphoma

rendering of Doxorubicin molecules
December 13, 2024/Cancer/News & Insight

Research Offers Further Insight into Chemo Scheduling for Early Breast Cancer

Phase 3 trial found no survival differences between weekly or biweekly doxorubicin/cyclophosphamide or between weekly or biweekly paclitaxel

BackPage 1 of 137Next

Advertisement

Ad